Classifications of Controlled Substances: Insights from 23 Countries

Dragic, Lisa; Lee, Elease; Wertheimer, Albert I.

doi:10.24926/iip.v6i2.383

Cited by 4 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Variations in national legislation and regulation about opioid prescribing exist between countries, for example, the duration of opioid prescriptions 10,41,42 and differences in definitions of opioid‐related adverse events due to the variations in public health priorities 6,43,44 . To ensure comparability in estimated opioid utilization between countries, determinants which cannot be identified from the secondary data sources, such as prescribers' knowledge, opioid accessibility, and prescribing regulations, should be explored in a multicentre survey to complement the comparative study.…”

Section: Discussionmentioning

confidence: 99%

“…In addition to the variation in patients' characteristics, [34][35][36] several determinants, including the accessibility of services, 34 insurance coverage and benefits policy, 37 national clinical guidelines and the healthcare system may also contribute to the variation in opioid prescribing, leading to incomparability in estimated opioid utilization between countries. 21,[38][39][40] Variations in national legislation and regulation about opioid prescribing exist between countries, for example, the duration of opioid prescriptions 10,41,42 and differences in definitions of opioid-related adverse events due to the variations in public health priorities. 6,43,44 To ensure comparability in estimated opioid utilization between countries, determinants which cannot be identified from the secondary data sources, such as prescribers' knowledge, opioid accessibility, and prescribing regulations, should be explored in a multicentre survey to complement the comparative study.…”

Section: Population Coverage Of Included Individual Patient-level Dat...mentioning

confidence: 99%

See 1 more Smart Citation

Feasibility and validity of using healthcare databases to conduct cross‐national comparative studies of opioid use, its determinants and consequences

Chen

Wettermark

Steinke

et al. 2023

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Purpose: A cross-national comparative (CNC) study about opioid utilization would allow the identification of strategies to improve pain management and mitigate risk.However, little is known about the accessibility and validity of information in healthcare databases internationally. This study aimed to identify the feasibility of using healthcare databases to conduct a CNC study of opioid utilization and its associated consequences. Methods: A cross-sectional survey was launched in March 2018, including experts interested in CNC studies comparing opioid utilization by purposeful sampling. An electronic survey was used to collect database characteristics, medicine information, and linkage information of each aggregate-level dataset (AD) and individual patientlevel dataset (IPD).Results: Overall, participants from 21 geographical regions reported 18 ADs and 19 IPDs. Information on dispensed medications is available from 17 ADs and 17 IPDs.Of the 16 ADs that include primary care settings, only 9 ADs can obtain information from secondary care settings. Fourteen IPDs included patients' characteristics or could be retrieved from linkage databases. Although most ADs are publicly accessible (n = 13), only five IPDs can be accessed without extra cost. Conclusion:Most ADs could be used to report opioid utilization in a primary care setting. IPDs with linkage databases should be applied to identify potential determinants, clinical outcomes, and policy impact. Data access restrictions and governance policies across jurisdictions can be challenging for timely analysis and require further collaboration.

show abstract

Section: Discussionmentioning

confidence: 99%